Home › Funds › Fairmount Funds Management LLC › DNTH

Fairmount Funds Management LLC position in DNTH

DIANTHUS THERAPEUTICS INC COM · Health Care

Fairmount Funds Management LLC reported holding 2,537,191 shares of DNTH (DIANTHUS THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$247.3M, representing 16.35% of its reported portfolio and ranking #2 among its reported holdings. Fairmount Funds Management LLC has disclosed DNTH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.54M sh
Reported value held$247.33M
Portfolio Weight16.35%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Fairmount Funds Management LLC's DNTH position evolved

Fairmount Funds Management LLC first disclosed a stake in DNTH in Q3 2023 at 1,928,503 shares (US$26.4M). The position peaked in Q2 2026 at 2,537,191 shares, worth US$247.3M. Across 12 filings, Fairmount Funds Management LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 2,537,191 shares valued at US$247.3M. Notable position changes include a 43% increase in Q1 2024 (shares fell 14% over the following quarter), a 35% trim in Q4 2025 (shares rose 104% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.93M $26.36M New
Q4 2023 1.93M $20.06M Hold
Q1 2024 2.76M $82.89M Add
Q2 2024 2.76M $71.50M Hold
Q3 2024 2.70M $73.94M Reduce
Q4 2024 2.70M $58.88M Hold
Q1 2025 2.70M $48.99M Hold
Q2 2025 2.71M $50.43M Hold
Q3 2025 3.31M $130.14M Add
Q4 2025 2.14M $88.07M Reduce
Q1 2026 2.54M $212.92M Add
Q2 2026 2.54M $247.33M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DNTH and 13F data

DNTH (DIANTHUS THERAPEUTICS INC COM) is a Health Care company. 72 other funds we track also report a position in DNTH — the largest reported positions include Avidity Partners Management LP (US$205.1M), Octagon Capital Advisors LP (US$179.5M), TCG Crossover Management, LLC (US$163.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DNTH

All DNTH fund holders →

FAQ

How long has Fairmount Funds Management LLC held DNTH?

Fairmount Funds Management LLC has disclosed DNTH holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Fairmount Funds Management LLC's current position in DNTH?

As of Q2 2026, Fairmount Funds Management LLC holds 2.54M shares of DNTH (DIANTHUS THERAPEUTICS INC COM), valued at $247.33M, representing 16.35% of its reported portfolio and ranking #2.

Has Fairmount Funds Management LLC been buying or selling DNTH?

In the latest 13F filing (Q2 2026), Fairmount Funds Management LLC held unchanged its position in DNTH. The position peaked in Q2 2026 at 2.54M shares.

Which other funds hold DNTH?

Other major institutional holders of DNTH include Avidity Partners Management LP, Octagon Capital Advisors LP, TCG Crossover Management, LLC, among 72 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.